SCHEMBL7889185

SCHEMBL7889185

C=C[C@H](C)CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL313933 1.00
SCHEMBL7883560 1.00
Phosphoric Acid SCHEMBL21683370 0.87 LAP3 (0.32)
SCHEMBL2030735 0.87 TSHR (0.50)
Nitrous Acid SCHEMBL7088089 0.87
SCHEMBL18035816 0.81 LMNA (0.52)
SCHEMBL12202970 0.75
SCHEMBL19302224 0.75
SCHEMBL616352 0.75
SCHEMBL11473800 0.75 TSHR (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3781574-B1 MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS ASCENTAGE PHARMA SUZHOU CO LTD (CN) 2023-05-10 EP disclosed
US-11498928-B2 Macrocyclic spiroethers as Mcl-1 inhibitors ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2022-11-15 US disclosed
CN-112867722-B MACROCYCLIC SPIROETHERS (MACROCYCLIC SPIROETHERS) as MCL-1 inhibitors 苏州亚盛药业有限公司 2022-09-23 CN disclosed
US-20210340158-A1 MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS ASCENTAGE PHARMA GROUP CORP LIMITED (CN) 2021-11-04 US disclosed
US-20210340158-A1 MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS ASCENTAGE PHARMA GROUP CORP LIMITED (CN) 2021-11-04 US disclosed
CN-112867722-A MACROCYCLIC SPIROETHERS (MACROCYCLIC SPIROETHERS) as MCL-1 inhibitors 苏州亚盛药业有限公司 2021-05-28 CN disclosed
EP-3781574-A1 MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS Ascentage Pharma (Suzhou) Co., Ltd. (CN) 2021-02-24 EP disclosed
WO-2020147802-A1 MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2020-07-23 WO disclosed
US-20140336240-A1 METHOD OF TREATING HYPERLIPIDEMIA AND ATHEROSCLEROSIS WITH MIR-30C THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2014-11-13 US disclosed
US-8691982-B2 Pyrazolo[1,5-a]-1,3,5-triazine derivatives, preparation thereof, and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2014-04-08 US disclosed
US-8691982-B2 Pyrazolo[1,5-a]-1,3,5-triazine derivatives, preparation thereof, and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2014-04-08 US disclosed
EP-2406263-B1 PYRAZOLO[1,5-A]-1,3,5-TRIAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF CENTRE NAT RECH SCIENT (FR) 2013-09-25 EP disclosed
US-20120184557-A1 PYRAZOLO[1,5-A]-1,3,5-TRIAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-07-19 US disclosed
US-20120184557-A1 PYRAZOLO[1,5-A]-1,3,5-TRIAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-07-19 US disclosed
WO-2010103486-A1 PYRAZOLO[1,5-A]-1,3,5-TRIAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2010-09-16 WO disclosed